There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ARS Pharmaceuticals (SPRY – Research Report) and ...

Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) is expected to release its earnings data before the market opens on ...

Terns Pharmaceuticals (TERN – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Equities researchers at William Blair started coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) in a research note issued to investors on Friday, Marketbeat reports. The firm ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a ...

Alcoholic and non-alcoholic fatty liver disease (NAFLD) are well-known risk factors for colorectal cancer (CRC). NAFLD has ...

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 ...

Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule ...

Terns Pharmaceuticals ( ($TERN) ) has issued an announcement. On February 22, 2025, Terns Pharmaceuticals announced the appointment of Andrew ...